Biotechnology

ArrowHead Pharma

Arrowhead Advances RNAi Pipeline, REDEMPLO Launches with Over 400 Prescriptions in First Quarter

Arrowhead Pharmaceuticals Announces Q2 2026 Earnings Report with Increased Net Loss

Arrowhead Pharmaceuticals Q2 Revenue Falls Short of Estimates

ArrowHead Pharma released FY2026 Semi-Annual earnings on May 7 During-Market (EST), actual revenue USD 337.77 M, actual EPS USD -0.73

ArrowHead Pharma released FY2026 Q2 earnings on May 7 During-Market EST, actual revenue USD 73.74 M (forecast USD 71.71 M), actual EPS USD -0.9319 (forecast USD -1.115)

Arrowhead Pharmaceuticals Licenses MASH Therapy to Madrigal Pharmaceuticals

Arrowhead's Redemplo Receives TGA Approval in Australia

ArrowHead Pharma to Release FY2026 Q2 Earnings on May 7 During-Market EST, Forecast Revenue USD 66.58 M, EPS USD -1.16

Arrowhead Pharmaceuticals CFO Joseph Appel sells company stocks

Arrowhead's siRNA Drug Redemplo Receives Positive Opinion from EMA

Arrows 制药 ReleasesNewDataonPlozasiranforHighTriglycerides

Arrowhead Pharmaceuticals presents drug development pipeline at TD Cowen conference

HC Wainwright Downgrades Arrowhead Pharmaceuticals Earnings Estimate

ArrowHead Pharma released FY2026 Q1 earnings on February 5 After-Market EST, actual revenue USD 264.03 M (forecast USD 230.85 M), actual EPS USD 0.22 (forecast USD -0.1455)

Arrowhead Pharmaceuticals Reports Q1 2026 Revenue of $264 Million, Exceeding Estimates

Arrowhead Pharmaceuticals Reports Q1 Financial Results

ArrowHead Pharma to Release FY2026 Q1 Earnings on February 5 After-Market EST, Forecast Revenue USD 230.85 M, EPS USD -0.1455

Arrowhead Pharmaceuticals Launches Clinical Trial for New RNA Therapy for Dyslipidemia

Arrowsmith Obtains Major Approval and Financing for REDEMPLO

Bayforest Capital Ltd Significantly Reduces Holdings in Arrowhead Pharmaceuticals

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

ARWR

SBIO

LABU

ARKG

Arrowhead Pharmaceuticals Director Hongbo Lu sold 2,970 shares at $76.88 each, totaling $228,333.60, reducing his stake by 5.40%. Post-sale, he holds 52,012 shares valued at approximately $3.99 million. The transaction was disclosed to the SEC and executed under a Rule 10b5-1 plan. The stock recently traded up 2.3% to $79.69, with a market cap of $11.23 billion and a negative earnings per share of -$0.93 for the last quarter.

Market Beat

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

iShares US Pharma

Ark Genomic Revolution ETF

VanEck Biotech ETF

iShares Biotechnology ETF

Direxion S&P Biotech Bear 3X

VG Health

Bank of Nova Scottia

JPMorgan Chase

ROYAL BANK OF CANADA

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B Riley Financial Pref Share RILYP 6.875 Perp 10/07/24

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) Director Sells 2,970 Shares of Stock

IBBQ

HC Wainwright has revised its Q3 2026 earnings estimate for Arrowhead Pharmaceuticals (NASDAQ:ARWR), lowering it to ($1.03) per share from ($1.02). The firm maintains a "Buy" rating with a target price of $100. Other analysts have also adjusted their ratings and target prices, with a consensus rating of "Moderate Buy" and an average target of $87.80. Arrowhead's stock has seen fluctuations, currently priced at $77.88, with a market cap of $10.97 billion. The company reported a revenue of $73.74 million for the last quarter, down 86.4% year-over-year.

Invesco Nasdaq Biotechnology ETF

Morgan Stanley

M&T Bank

Nordea Bank

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

M & T BANK CORP DEP SHS REPSTG 1/400TH INT PERP SER K

M & T BANK CORP PERP NON CUM PFD FIXED FLTG RATE SER H

M & T BANK CORP DEP SHS EA REP 1/400TH SHS SERIES J

What is HC Wainwright's Forecast for ARWR Q3 Earnings?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is advancing its RNA interference pipeline while entering a commercial phase, as stated by CEO Chris Anzalone at the BofA Annual Healthcare Conference. The company has launched REDEMPLO for familial chylomicronemia syndrome, achieving over 400 prescriptions in its first quarter. Arrowhead anticipates pivotal data from SHASTA studies on triglyceride reduction and pancreatitis benefits. Anzalone projects peak U.S. sales for REDEMPLO could reach $3-4 billion, emphasizing the need for physician education in the market.

Bank of America

Ionis Pharma

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Sanford C. Bernstein has raised its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) from $35.00 to $46.00, maintaining a "market perform" rating. This new target suggests a potential downside of 41.47% from the previous close. Other analysts have varying ratings and price targets, with a consensus rating of "Moderate Buy" and an average target price of $87.80. Arrowhead's stock recently traded at $78.59, with a market cap of $11.07 billion and a negative net margin of 48.38%.

Piper Sandler Cos

Weis Markets

Sanford C. Bernstein Boosts Arrowhead Pharmaceuticals (NASDAQ:ARWR) Price Target to $46.00

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

nasdaq

Nasdaq

Arrowhead (ARWR) Q2 2026 Earnings Transcript

Earnings Watch

ArrowHead Pharma | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 73.74 M

MDGL

BAYRY

Madrigal Pharmaceuticals and Bayer are actively engaging in mergers and acquisitions to enhance their pharmaceutical pipelines. Madrigal has secured a global license for ARO-PNPLA3 from Arrowhead Pharmaceuticals, valued at over $1 billion, targeting a genetic factor in metabolic dysfunction-related liver diseases. Meanwhile, Bayer is acquiring Perfuse Therapeutics for up to $2.45 billion to develop PER-001, aimed at treating glaucoma and diabetic retinopathy. Both companies are focusing on innovative therapies to address significant health issues.

Pharmexec

Madrigal Pharma

Bayer

Bayer Aktiengesellschaft

SPDR S&P Health Equip

Bayer AG

<![CDATA[Pharma M&A Roundup: Bayer to Acquire Perfuse Therapeutics, Madrigal Enters Licensing Agreement for ARO-PNPLA3]]>

Arrowhead Pharma shares are trading lower. The company announced an exclusive worldwide license agreement with Madrigal Pharma for ARO-PNPLA3 as potential treatment for metabolic dysfunction-associated steatohepatitis.

benzinga_article

ArrowHead Pharma(ARWR.US)